We offer analyses of the blood levels of active metabolites in patients with toxic covalent binding inhibitors, a group of pharmaceuticals that are commonly hard to measure and dose. Currently we provide methods with high sensitivity for several common cytostatic. We also develop tailor made methods for analyses of other reactive metabolites that bind covalently to biomarkers. The result can be used either to adjust the dose or as a marker for compliance in the case of a long term dose regimen.
The measurement only requires a simple blood sample that without further treatment can be sent to our lab in Södertälje for analyses. We work according to GLP and have a long term experience of handling patient samples.
Fast analysis, fast answers
Better understanding of the treatment
Increased patient safety
Less side effects due to over dosing
Fewer patients with less than the desired active dose
The study was conducted with the main objective to evaluate biomarkers as a tool for individual dose adjustments. We wanted to look at correlations between biomarker and toxicity. The secondary aim was to look at correlations with single nucleotide polymorphism genotype data to evaluate whether patients in risk of under or overdose can be predicted via genetic markers. TailorDose was used as a method for determination of in vivo dose of the active components in cytostatic treatment in women with breast cancer.
Clinical samples was gathered between 2012 and 2014 resulting i a clinical cohort of 152 breast cancer patients treated with cyclophospamid and we acquired adduct data from a total of 471 dose cycles. The results are promising and we found a strong correlation between Age and Dose biomarker, indicating that older patients recieves higher in vivo doses of active PAM. Further results are statistically evaluated and a manuscript under way.
Ongoing study at Karolinska Institutet furthering the studies on therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer. The study encompasses female breast cancer patients receiving FEC or EC treatment (epirubicin and cyclophosphamide) with or without subsequent docetaxel or paclitaxel therapy, and patients receiving neo-adjuvant or adjuvant TAC (docetaxel, doxorubicin and cyclophosphamide) will be monitored with a novel strategy consisting of:
TailorDose®, a patented technology which enables exposure measurements of PAM, formed from cyclophosphamide, by analyzing the level of a specific biomarker.
A model based therapeutic drug monitoring approach to measure exposures for epirubicin, doxorubicin, docetaxel, and paclitaxel.